Scarica l'app Stockscreener
0.9331
0.33%
0.0031
Precedente Chiudi:
$0.93
Aprire:
$0.9335
Volume 24 ore:
28,926
Relative Volume:
0.16
Capitalizzazione di mercato:
$30.43M
Reddito:
-
Utile/perdita netta:
$-12.29M
Rapporto P/E:
-0.8973
EPS:
-1.0399
Flusso di cassa netto:
$-9.07M
1 W Prestazione:
-8.97%
1M Prestazione:
+18.26%
6M Prestazione:
-12.79%
1 anno Prestazione:
-65.44%
Intervallo 1D:
$0.9316
$0.9696
Intervallo di 1 settimana:
$0.91
$1.105
Portata 52W:
$0.5714
$3.15
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(646) 350-0702
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta AKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.9331 | 30.33M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.20 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.36 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.24 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
807.98 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Maxim Group | Buy |
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics files new patents for cancer treatment technology - Investing.com
Akari Therapeutics Files Two Provisional Patents for PH1 | AKTX Stock News - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akari Therapeutics Plc Adr Azioni (AKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | CEO |
Aug 22 '25 |
Buy |
0.93 |
8,000 |
7,440 |
295,574 |
| Gaslightwala Abizer | CEO |
Aug 25 '25 |
Buy |
0.90 |
3,000 |
2,700 |
298,574 |
| Gaslightwala Abizer | President & CEO |
Jun 24 '25 |
Buy |
1.16 |
5,203 |
6,035 |
277,574 |
| Gaslightwala Abizer | President & CEO |
Jun 23 '25 |
Buy |
1.15 |
943 |
1,084 |
272,371 |
| Gaslightwala Abizer | President & CEO |
Jun 20 '25 |
Buy |
1.20 |
10,000 |
12,000 |
271,428 |
| Gaslightwala Abizer | President & CEO |
Jun 17 '25 |
Buy |
1.20 |
15,000 |
18,000 |
261,428 |
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):